Hepatobiliary Cancer clinical trials

Explore recruiting hepatobiliary cancer clinical trials.

Recruiting hepatobiliary cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatobiliary Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE 1/2, OPEN-LABEL, MULTICENTER, FIRST IN-HUMAN STUDY OF DS-3939a IN SUBJECTS WITH ADVANCED SOLID TUMORS

France, Spain, Belgium

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Hepatobiliary Cancer trials by city

Hepatobiliary Cancer clinical trials

Recruiting hepatobiliary cancer studies right now

A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

Targeted Navigation in Hepatocellular Carcinoma (HCC)

Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

Ligufalimab and Cadonilimab in Advanced Liver Cancers

SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

Acceptance and Commitment Therapy (ACT-HBC) for the Improvement of Cancer Distress in Patients With Hepatobiliary Cancers

Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration

Also recruiting in Europe

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

PHASE 1/2, OPEN-LABEL, MULTICENTER, FIRST IN-HUMAN STUDY OF DS-3939a IN SUBJECTS WITH ADVANCED SOLID TUMORS

Hepatobiliary Cancer trials by city

Other conditions